Critical illness polyneuropathy

disease

On this page

Summary

Critical illness polyneuropathy (MONDO:0001957) is a disease and 12 clinical trials. Top therapeutic interventions include testosterone cypionate. A subtype of polyneuropathy — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

Clinical trials: 12

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	critical illness polyneuropathy
Mondo ID	MONDO:0001957
DOID	DOID:14402
ICD-10-CM	G62.81
SNOMED CT	230594005
UMLS	C0393851
MedGen	140748
GARD	0023046
Is cancer (heuristic)	no

Disease family

This is a subtype of polyneuropathy. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › nervous system disorder › peripheral nervous system disorder › peripheral neuropathy › polyneuropathy › critical illness polyneuropathy

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 12.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	11
PHASE2/PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT03038919	PHASE2/PHASE3	UNKNOWN	Role of Anabolic Steroids on Intensive Care Unit-Acquired Weakness
NCT03810768	Not specified	RECRUITING	Metabolomics Study on Postoperative Intensive Care Acquired Muscle Weakness
NCT06419699	Not specified	ACTIVE_NOT_RECRUITING	CPAx: Responsiveness and Minimal Clinically Important Difference
NCT06786390	Not specified	RECRUITING	Improved Recovery of Walking in Acquired Muscle Weakness
NCT07478367	Not specified	RECRUITING	Critical Illness Weakness Outside the Intensive Care Unit.
NCT07594249	Not specified	NOT_YET_RECRUITING	Shear Wave Elastography of Peripheral Nerves for Early Diagnosis of ICU-acquired Weakness
NCT02763709	Not specified	UNKNOWN	Evaluation of Pediatric Critical Illness Neuropathy/Myopathy in Pediatric Intensive Care Unit
NCT02976415	Not specified	COMPLETED	In-Bed Cycling in ICU Patients Post Cardiac Surgery
NCT03616314	Not specified	COMPLETED	Effects of Early Stepping Verticalization + FES on CIP
NCT03819959	Not specified	COMPLETED	Metabolomics Study on Intensive Care Acquired Muscle Weakness in Polytrauma
NCT03893058	Not specified	UNKNOWN	Evaluation of the NeuroMuscular Junction Using the Single Fiber Electromyography and Reliability of Train-Of-Four in Critically Ill Patients.
NCT04193943	Not specified	UNKNOWN	Validation of Simplified Electrophysiological Examination in the Diagnosis of Critical Illness Myopathy or Neuropathy

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
TESTOSTERONE CYPIONATE	4	1

Drugs: Testosterone Cypionate